Drug intelligence / Profile preview

pfs25m-epa

Development stage: Phase 1
Lead developer: National Institutes of Health
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Pfs25M-EPA is a malaria transmission-blocking vaccine candidate consisting of a recombinant form of Plasmodium falciparum surface protein Pfs25 (specifically the Pfs25M variant) chemically conjugated to ExoProtein A (EPA), a recombinant mutant and detoxified protein from Pseudomonas aeruginosa. The Pfs25M variant was developed to remove heterologous amino acid residues present in an earlier version (Pfs25H). This vaccine is designed to interrupt the malaria parasite's life cycle by targeting sexual stage development in mosquitoes, specifically zygotes and ookinetes.

Other names: Pfs25M-EPA/Alhydrogel

Targets

Pfs25

Beyond the preview

Go deeper on pfs25m-epa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pfs25m-epa.

Explore the full profile